Professionals 214 results
Capabilities 55 results
Practice Area
Practice Area
Practice Area
Bankruptcy Litigation & Investigations
Experience 70 results
Experience
|April 29, 2025
Stream Realty Completes Ownership Transfer of Houston Center
Experience
|April 23, 2025
Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination
Experience
|March 31, 2025
Insights & News 601 results
Sponsorship
|September 18, 2025
Winston Sponsors New York Office Leasing & Asset Management Conference
Client Alert
|August 8, 2025
|5 Min Read
The One Big Beautiful Bill Act, enacted on July 4, 2025, modernizes and expands the already favorable tax treatment that applies to investments in qualified small business stock (QSBS). These changes benefit venture capital funds that intend to avail themselves of the tax benefits under the QSBS rules by (i) expanding the universe of companies that the funds can invest in, (ii) increasing the amount of gains that their respective investors can receive that are not subject to federal income tax and (iii) providing the funds with more flexibility in terms of timing their exits from these types of investments. The expansion of the QSBS rules under the Act should be a welcome development for venture capital funds and their investors.
Non-Fungible Insights: Blockchain Decrypted
|July 31, 2025
|4 Min Read
Preparing for Change: FCA Consultations Redefine the UK Digital Assets Regulatory Landscape
2025 is shaping up to be a pivotal year for the regulation of digital assets in the UK. As the European Union’s Markets in Crypto-Assets is reshaping the EU’s regulatory landscape by introducing a unified framework for crypto-asset service providers, the UK Financial Conduct Authority is advancing its own agenda, guided by its Cryptoasset Roadmap, to ensure regulatory clarity while supporting innovation.
Other Results 30 results
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
Law Glossary
What Is the Difference Between a Biosimilar and a Generic Drug?